ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Biomedical Advanced Research & Development Authority has committed to supporting two companies’ early-stage development of Zika vaccines. Japan’s Takeda Pharmaceutical will receive $20 million over 18 months to complete preclinical work and a Phase I clinical trial of its inactivated whole-virus vaccine. BARDA is also putting $8 million over four years into similar work at Moderna Therapeutics on its mRNA-based vaccine. BARDA may extend the agreements for another five to six years, putting Takeda in a position to receive up to $311 million and Moderna up to $126 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter